Taken together, these data raise the possibility that deleting Ng2/Cspg4 at tumor initiation activates IGF signaling, a pathway known to positively regulate soft-tissue sarcoma growth (42), whereas in established tumors, there is an opposite effect. The gene discussed is CSPG4; the disease is soft tissue sarcoma.